Rita Petracca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rita Petracca has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Kosta Besermenji
Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, David De Wied Building, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
4 shared publicationsMarinda Westerveld
Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, David De Wied Building, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
4 shared publicationsDavid Aidukas
Department of Pharmaceutical Sciences Faculty of Science Utrecht University David De Wied Building, Universiteitsweg 99 3584 CG Utrecht NL
2 shared publicationsNikita Ostrovitsa
Trinity Biomedical Sciences Institute (TBSI) Trinity College Dublin (TCD) 152-160 Pearse St. Dublin D02 R590 Ireland
2 shared publications- Sean M. McKenna
Leiden University
2 shared publications - Andrii Monastyrskyi
Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
1 shared publication
Latest Publications
- Open Access
Rational Design of a Photoactivated Fluorescent Probe for Thiol-ene Mediated Protein Labelling
Fluorescent labelling of biomolecules enables the visualization and tracking of molecular processes in cells, providing insights into cellular function and disease mechanisms. Despite recent advances in bioorthogonal labelling, efficient and site-selective strategies for targeting alkene functionalities remain limited. Here, we report AbzSH, a compact aminobenzamide-based fluorescent thiol probe for selective alkene labelling through thiol–ene ligation. Photoinduced ligation proceeds under mild, radical-mediated conditions in aqueous media and exhibits broad substrate compatibility, including carbohydrate, amino acid, and steroid scaffolds. The method is readily extended to protein labelling, enabling selective modification of both chemically functionalized proteins and engineered proteins containing genetically encoded alkene motifs. Efficient and chemoselective labelling was further demonstrated in complex cell lysates, highlighting the robustness of the approach in biologically relevant environments. Collectively, these results establish AbzSH as a versatile fluorescent probe for alkene-directed biomolecular labelling and provide a broadly applicable platform for chemical biology, molecular imaging, proteomics, and drug discovery. TOC Graphic: Thiol-ene mediated ‘click’ labelling of an alkene-bearing protein in complex cell lysate using a fluorescent thiol probe.
Open AccessRational Design of a Photoactivated Fluorescent Probe for Thiol-ene Mediated Protein Labelling
Fluorescent labelling of biomolecules enables the visualization and tracking of molecular processes in cells, providing insights into cellular function and disease mechanisms. Despite recent advances in bioorthogonal labelling, efficient and site-selective strategies for targeting alkene functionalities remain limited. Here, we report AbzSH, a compact aminobenzamide-based fluorescent thiol probe for selective alkene labelling through thiol–ene ligation. Photoinduced ligation proceeds under mild, radical-mediated conditions in aqueous media and exhibits broad substrate compatibility, including carbohydrate, amino acid, and steroid scaffolds. The method is readily extended to protein labelling, enabling selective modification of both chemically functionalized proteins and engineered proteins containing genetically encoded alkene motifs. Efficient and chemoselective labelling was further demonstrated in complex cell lysates, highlighting the robustness of the approach in biologically relevant environments. Collectively, these results establish AbzSH as a versatile fluorescent probe for alkene-directed biomolecular labelling and provide a broadly applicable platform for chemical biology, molecular imaging, proteomics, and drug discovery. TOC Graphic: Thiol-ene mediated ‘click’ labelling of an alkene-bearing protein in complex cell lysate using a fluorescent thiol probe.
- Open Access
A potent macrocyclic peptide binder enables effector-free crystallization of the GTPase RAB27A
RAB27A is a member of a highly conserved family of small GTPases that regulate intracellular vesicle trafficking. Multiple studies have linked RAB27A cellular activity to exosome-mediated modulation of the tumour microenvironment and inflammatory signalling, highlighting it as an attractive target for drug discovery. However, identifying structurally validated and selective inhibitors of the RAB27A-effector interaction has proven challenging, partly because wild-type RAB27A crystallizes only in complex with effector proteins such as Slp2a. Using mRNA display, we identified macrocyclic peptide ligands that target the RAB27A effector-binding interface. Optimisation of initial hits led to IMP2660 , a nanomolar-affinity RAB27A binder that effectively disrupts RAB27A-effector interactions. IMP2660 enabled determination of a 2.1 Å structure of active-state RAB27A bound to a noncovalent macrocyclic peptide in the absence of an effector, revealing structural features of the effector-binding surface and providing a platform for future structure-guided ligand development.
Open AccessA potent macrocyclic peptide binder enables effector-free crystallization of the GTPase RAB27A
RAB27A is a member of a highly conserved family of small GTPases that regulate intracellular vesicle trafficking. Multiple studies have linked RAB27A cellular activity to exosome-mediated modulation of the tumour microenvironment and inflammatory signalling, highlighting it as an attractive target for drug discovery. However, identifying structurally validated and selective inhibitors of the RAB27A-effector interaction has proven challenging, partly because wild-type RAB27A crystallizes only in complex with effector proteins such as Slp2a. Using mRNA display, we identified macrocyclic peptide ligands that target the RAB27A effector-binding interface. Optimisation of initial hits led to IMP2660 , a nanomolar-affinity RAB27A binder that effectively disrupts RAB27A-effector interactions. IMP2660 enabled determination of a 2.1 Å structure of active-state RAB27A bound to a noncovalent macrocyclic peptide in the absence of an effector, revealing structural features of the effector-binding surface and providing a platform for future structure-guided ligand development.
- 14 January 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (2)
Cover Feature: Cracking Lysine Crotonylation (Kcr): Enlightening a Promising Post‐Translational Modification (ChemBioChem 2/2025)
- 14 January 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (2)
Cover Feature: Cracking Lysine Crotonylation (Kcr): Enlightening a Promising Post‐Translational Modification (ChemBioChem 2/2025)
- 2 December 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (12) , 2094
The mystery of crotonyl-CoA
- 2 December 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (12) , 2094
The mystery of crotonyl-CoA
- 21 November 2024
- Published by Wiley in ChemMedChem
- Vol. 20 (4) , e202400853
Highlights from the Lowlands: Early Career Researchers Shine at Medicinal Chemistry Frontiers 2024
EFMC‐ACS MEDI Medicinal Chemistry Frontiers 2024 welcomed scientists from across Europe and the USA to share their research at a Spring meeting hosted in the Netherlands. A stellar lineup of speakers including industry luminaries and academic leaders delivered presentations on their research, encompassing a wide variety of topics in drug discovery. The event also proved to be a worthy showcase for many wonderfully talented early career researchers in medicinal chemistry and chemical biology. Presented here are some of the notable themes and activities, as well as perspectives from the event.
- 21 November 2024
- Published by Wiley in ChemMedChem
- Vol. 20 (4) , e202400853
Highlights from the Lowlands: Early Career Researchers Shine at Medicinal Chemistry Frontiers 2024
EFMC‐ACS MEDI Medicinal Chemistry Frontiers 2024 welcomed scientists from across Europe and the USA to share their research at a Spring meeting hosted in the Netherlands. A stellar lineup of speakers including industry luminaries and academic leaders delivered presentations on their research, encompassing a wide variety of topics in drug discovery. The event also proved to be a worthy showcase for many wonderfully talented early career researchers in medicinal chemistry and chemical biology. Presented here are some of the notable themes and activities, as well as perspectives from the event.
- 27 October 2024
- Published by Wiley in ChemBioChem
- Vol. 25 (24) , e202400638
Rewiring Lysine Catabolism in Cancer Leads to Increased Histone Crotonylation and Immune Escape
Crotonyl‐CoA (cr‐CoA) is a metabolite derived directly from the catabolism of lysine (Lys) and tryptophan (Trp) or from the β‐oxidation of fatty acids. In glioblastoma stem cells (GSCs), histone H4 crotonylation levels are significantly elevated, which appears to positively correlate with tumor growth. This increase in crotonyl‐CoA production is attributed to the overexpression of specific Lys transporters on the cell membrane, leading to higher free lysine levels. Additionally, the overexpression of glutaryl‐CoA dehydrogenase (GCDH), the enzyme responsible for crotonyl‐CoA production, further contributes to this increase. When GCDH is depleted or under a lysine‐restricted diet, genes involved in type I interferon (IFN) signaling are upregulated, resulting in tumor growth suppression. Type I interferons are a group of cytokines critical for antiviral responses and immunoregulation. This highlights how cancer cells exploit crotonylation to modulate the immune response. This work opens up new avenues for investigating how cancer cells rewire their metabolism to increase crotonylation and evade the immune system.
- 27 October 2024
- Published by Wiley in ChemBioChem
- Vol. 25 (24) , e202400638
Rewiring Lysine Catabolism in Cancer Leads to Increased Histone Crotonylation and Immune Escape
Crotonyl‐CoA (cr‐CoA) is a metabolite derived directly from the catabolism of lysine (Lys) and tryptophan (Trp) or from the β‐oxidation of fatty acids. In glioblastoma stem cells (GSCs), histone H4 crotonylation levels are significantly elevated, which appears to positively correlate with tumor growth. This increase in crotonyl‐CoA production is attributed to the overexpression of specific Lys transporters on the cell membrane, leading to higher free lysine levels. Additionally, the overexpression of glutaryl‐CoA dehydrogenase (GCDH), the enzyme responsible for crotonyl‐CoA production, further contributes to this increase. When GCDH is depleted or under a lysine‐restricted diet, genes involved in type I interferon (IFN) signaling are upregulated, resulting in tumor growth suppression. Type I interferons are a group of cytokines critical for antiviral responses and immunoregulation. This highlights how cancer cells exploit crotonylation to modulate the immune response. This work opens up new avenues for investigating how cancer cells rewire their metabolism to increase crotonylation and evade the immune system.
- Open Access
- 27 October 2024
- Published by Wiley in ChemBioChem
- Vol. 26 (2) , e202400639
Cracking Lysine Crotonylation (Kcr): Enlightening a Promising Post‐Translational Modification
Lysine crotonylation (Kcr) is a recently discovered post‐translational modification (PTM). Both histone and non‐histone Kcr‐proteins have been associated with numerous diseases including cancer, acute kidney injury, HIV latency, and cardiovascular disease. Histone Kcr enhances gene expression to a larger extend than the extensively studied lysine acetylation (Kac), suggesting Kcr as a novel potential therapeutic target. Although numerous scientific reports on crotonylation were published in the last years, relevant knowledge gaps concerning this PTM and its regulation still remain. To date, only few selective Kcr‐interacting proteins have been identified and selective methods for the enrichment of Kcr‐proteins in chemical proteomics analysis are still lacking. The development of new techniques to study this underexplored PTM could then clarify its function in health and disease and hopefully accelerate the development of new therapeutics for Kcr‐related disease. Herein we briefly review what is known about the regulation mechanisms of Kcr and the current methods used to identify Kcr‐proteins and their interacting partners. This report aims to highlight the significant potential of Kcr as a therapeutic target and to identify the existing scientific gaps that new research must address.
- 27 October 2024
- Published by Wiley in ChemBioChem
- Vol. 26 (2) , e202400639
Open AccessCracking Lysine Crotonylation (Kcr): Enlightening a Promising Post‐Translational Modification
Lysine crotonylation (Kcr) is a recently discovered post‐translational modification (PTM). Both histone and non‐histone Kcr‐proteins have been associated with numerous diseases including cancer, acute kidney injury, HIV latency, and cardiovascular disease. Histone Kcr enhances gene expression to a larger extend than the extensively studied lysine acetylation (Kac), suggesting Kcr as a novel potential therapeutic target. Although numerous scientific reports on crotonylation were published in the last years, relevant knowledge gaps concerning this PTM and its regulation still remain. To date, only few selective Kcr‐interacting proteins have been identified and selective methods for the enrichment of Kcr‐proteins in chemical proteomics analysis are still lacking. The development of new techniques to study this underexplored PTM could then clarify its function in health and disease and hopefully accelerate the development of new therapeutics for Kcr‐related disease. Herein we briefly review what is known about the regulation mechanisms of Kcr and the current methods used to identify Kcr‐proteins and their interacting partners. This report aims to highlight the significant potential of Kcr as a therapeutic target and to identify the existing scientific gaps that new research must address.
- 10 October 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (86) , 11810-11813
Novel activity-based probes for N-acylethanolamine acid amidase
The cysteine hydrolase, N-acylethanolamine acid amidase (NAAA) is a promising target for analgesic and anti-inflammatory drugs. Here, we describe the development of two unprecedented NAAA-reactive activity-based probes as research tools for application in the discovery of new inhibitors and for the in-depth characterization of NAAA in its cellular environment.
- 10 October 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (86) , 11810-11813
Novel activity-based probes for N-acylethanolamine acid amidase
The cysteine hydrolase, N-acylethanolamine acid amidase (NAAA) is a promising target for analgesic and anti-inflammatory drugs. Here, we describe the development of two unprecedented NAAA-reactive activity-based probes as research tools for application in the discovery of new inhibitors and for the in-depth characterization of NAAA in its cellular environment.